Blood cancer player Imago Biosciences caps off an $80M Series C with an IPO promise for 2021
A little less than two years after securing $40 million in a Series B, Imago Biosciences has returned to the venture capital well with an even bigger prize.
The San Francisco-based biotech has pulled in $80 million for their Series C on Thursday, aiming to use the funds for one Phase III trial for their lead blood cancer program, bomedemstat. The experimental drug is being evaluated in two Phase IIb studies, in myelofibrosis and essential thrombocythemia.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.